dantrolene has been researched along with Chronic Disease in 6 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 9.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 5.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by treatment with nimodipine." | 1.42 | Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. ( Adzovic, L; Crockett, AM; D'Angelo, HM; Hopp, SC; Kaercher, RM; Royer, SE; Wenk, GL, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, S | 1 |
| Wakeyama, T | 1 |
| Ono, S | 1 |
| Ikeda, Y | 1 |
| Omura, M | 1 |
| Oda, T | 1 |
| Hisamatsu, Y | 1 |
| Seki, K | 1 |
| Satoh, A | 1 |
| Hiromoto, M | 1 |
| Akashi, S | 1 |
| Uchida, K | 1 |
| Harada, M | 1 |
| Furutani, Y | 1 |
| Nakamura, Y | 1 |
| Kohno, M | 1 |
| Kawamura, S | 1 |
| Obayashi, M | 1 |
| Michishige, H | 1 |
| Yano, M | 1 |
| Hopp, SC | 1 |
| D'Angelo, HM | 1 |
| Royer, SE | 1 |
| Kaercher, RM | 1 |
| Crockett, AM | 1 |
| Adzovic, L | 1 |
| Wenk, GL | 1 |
| Javed, M | 1 |
| Bogdanov, A | 1 |
| Weiser, R | 1 |
| Terenty, T | 1 |
| Hudgson, P | 1 |
| Weightman, D | 1 |
| Petusevsky, ML | 1 |
| Faling, LJ | 1 |
| Rocklin, RE | 1 |
| Snider, GL | 1 |
| Merliss, AD | 1 |
| Moses, JM | 1 |
| Dorman, SA | 1 |
| Lietman, PS | 1 |
| Haslam, RH | 1 |
| Walcher, JR | 1 |
2 trials available for dantrolene and Chronic Disease
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design.
Topics: Chronic Disease; Dantrolene; Double-Blind Method; Female; Heart Failure; Humans; Male; Morbidity; Re | 2020 |
Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dantrolene; Double-Blind Method; Female; Hum | 1978 |
4 other studies available for dantrolene and Chronic Disease
| Article | Year |
|---|---|
Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Calcium Chan | 2015 |
Oral dantrolene and severe respiratory failure in a patient with chronic spinal cord injury.
Topics: Administration, Oral; Chronic Disease; Dantrolene; Humans; Male; Middle Aged; Muscle Relaxants, Cent | 2010 |
Pleuropericardial reaction to treatment with dantrolene.
Topics: Acute Disease; Adult; Chronic Disease; Dantrolene; Female; Humans; Male; Middle Aged; Muscle Spastic | 1979 |
Pharmacology of dantrolene sodium in children.
Topics: Administration, Oral; Adolescent; Amines; Capsules; Child; Child, Preschool; Chronic Disease; Dantro | 1974 |